ClinicalTrials.gg

Hepatitis D, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 43 studies for Hepatitis D, Chronic across more than 10 countries. 9 are recruiting or about to start. 35 of them are mainly about Hepatitis D, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
19
Active, not recruiting
6
Recruiting
6
Status unknown
5
Terminated
2
Withdrawn
2

Phase

Phase 2
20
Phase 3
9
Phase 1
4
Phase 4
1

Where

Germany
12
Romania
11
Italy
10
France
9
United States
9
United Kingdom
8

Who develops what

Add Hepatitis D, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 7 with this as their studies’ main aim; 5 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Mirum Pharmaceuticals, Vir Biotechnology and Assembly Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bulevirtideRecent, limited
Evidence
  • NCT07142811 · Vir Biotechnology, Inc. · Phase 2 · live · background · “Bulevirtide” · registered Aug 2025
  • NCT07128550 · Vir Biotechnology, Inc. · Phase 3 · live · background · “Bulevirtide” · registered Aug 2025
Gilead Sciences80% of its industry studiesEU: Gilead Sciences (EMA 2020)12 studies
peginterferon alfa-2aEarlier only
Evidence
  • NCT02637999 · Hepatera Ltd. · Phase 2 · background · “PEG IFN alfa-2a” · registered Dec 2015
  • NCT02430181 · EIT Pharma, Inc. · Phase 2 · background · “peginterferon alfa-2a” · registered Apr 2015
Hoffmann-La Roche67% of its industry studiesUS: pharmaand GmbH (FDA 2002)EU: pharmaand GmbH (EMA 2002)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tobevibart☆ Track2 live phase-3 studies: NCT06903338, NCT07128550Vir Biotechnology, Inc.
elebsiran☆ Track2 live phase-3 studies: NCT06903338, NCT07128550Vir Biotechnology, Inc.
brelovitug☆ Track1 live phase-3 study: NCT07454837Mirum Pharmaceuticals, Inc.
bulevirtideApproved: EU 2020☆ Track1 live phase-3 study: NCT07454837Mirum Pharmaceuticals, Inc.
hepalatide☆ Track1 live phase-3 study: NCT07309380Shanghai HEP Pharmaceutical Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 2 registry mapping onlystudied with bulevirtideNCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48 · 100 enrolled
  • Dec 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 3 registry mapping onlystudied with bulevirtideNCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24 · 150 enrolled
  • Jun 2027 est.ABI-6250 · Assembly Biosciences · Phase 2 main aimNCT07762027 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection — primary endpoint: Proportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results. · 80 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis D, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

3studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Who these studies take

Of the 6 Hepatitis D, Chronic studies recruiting now, 4 (67%) set no upper age limit and 2 (33%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (33%) take healthy volunteers.

Recruiting studies that take each age, of 6
AgeWomenMen
100 (0%)0 (0%)
186 (100%)6 (100%)
306 (100%)6 (100%)
406 (100%)6 (100%)
506 (100%)6 (100%)
656 (100%)6 (100%)
754 (67%)4 (67%)
854 (67%)4 (67%)

Across all 43 studies, recruiting or not: 51% stop at 75 or younger and 35% at 65; 2% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 43 of 43. search them.